Frequently Asked Questions
The global central nervous system biomarkers market was valued at USD 4.2 Billion in 2022.
The central nervous system biomarkers market is expected to grow at a CAGR of 9.3% between 2023 and 2030, reaching USD 7.82 Billion in 2030.
Safety biomarkers are the leading segment by type, holding over 35% share in terms of value in 2022.
The drug discovery & development segment governs the global demand for central nervous system biomarkers, holding a massive share of over 38% in 2022.
The clinics/hospitals segment will post the highest CAGR in the projected period.
Asia Pacific is fueling the rapid growth of the central nervous system biomarkers industry, with an over one-third share in 2022.
The top players include Acumen Pharmaceuticals Inc, Bio-Rad Laboratories Inc, Merck KGaA, and Proteome Sciences PLC. Other major players include Thermo Fisher Scientific Inc, Enzo Biochem Inc, Acro Biosystems, and Eli Lilly & Company.
The major market drivers are the increasing prevalence of neurological disorders, growing demand for personalized medicine, advancements in biomarker discovery techniques, and the rising focus on early disease diagnosis.
The major market restraints are the high biomarker development and validation cost, stringent regulatory requirements, and the complexity of central nervous system diseases.
The major market opportunities in the central nervous system biomarkers industry include the development of novel biomarkers for various neurological conditions, increasing research and development activities, and the potential for collaborations and partnerships for biomarker discovery and validation.